Buy Senores Pharmaceuticals Ltd for the Target Rs.1,165 by Choice Institutional Equities
Business Overview:
Senores Pharmaceuticals (SENORES) develops and markets complex generics and niche formulations across regulated and emerging markets, exporting to 40+ countries. It operates a USFDA-approved oral solids facility in Atlanta and multiple plants in Gujarat (India), along with a new API unit for backward integration. The portfolio includes 51 approved owned ANDAs and a growing pipeline in peptides, injectables and specialty drugs, complemented by 478 approved products in emerging markets. Senores is also expanding its CDMO/CMO offering through strategic acquisitions, with Q4FY26 revenue showing strong double-digit growth across both, regulated and emerging markets.
How are regulated markets and Apnar-led scale-up shaping the next phase of growth for SENORES?
SENORES’ growth is primarily being driven by strong execution in regulated markets, where rapid expansion of its ANDA portfolio (from 26 to 51 approvals) and ~27 planned launches over the next 6-8 quarters provide strong revenue visibility. This is further strengthened by the Apnar facility, which has already commenced commercialisation and is expected to contribute INR 800-1,000 Mn in FY27E, scaling up to INR 1,800-2,000 Mn over the medium term. Together, these drivers significantly enhance the US scale, improve product flow and support sustained high growth momentum
What supports margin expansion and diversified earnings growth across emerging and branded markets?
Beyond regulated markets, SENORES is building a strong second engine through emerging markets and branded generics, supported by a large portfolio of 478 approved products and rapid geographic expansion. Emerging markets are increasingly focused on higher-value niche products, while branded generics in India are also scaling up, driven by deeper hospital penetration and portfolio expansion. This improving mix, combined with operating leverage from scale-up across segments, is expected to support sustained EBITDA margins of ~29–31% and strong PAT growth in FY27E.
Why Invest in SENORES?
SENORES is entering a high-growth phase supported by multiple levers:
* Strong Regulated Market Execution: The company is scaling up rapidly in the US generics, supported by expansion of its ANDA portfolio (26 → 51 approvals) and ~27 planned launches, including CGT and FTF opportunities, providing strong multiyear revenue visibility.
* Monetisation of Apnar-led Capacity Expansion: The newly integrated Apnar facility is entering its ramp-up phase, with expected revenue contribution of INR 800–1,000 Mn in FY27E, driving operating leverage and improving asset utilization.
* Margin Expansion: Backward integration through its API facility, coupled with better fixed-cost absorption and operating leverage from Apnar acquisition, is expected to drive EBITDA margin expansion in FY27E
Recommendation:
We currently have a ‘BUY’ rating on the stock with a target price of INR 1,165.
Key Risks:
* Execution Risk in US Launch Pipeline: The company remains heavily dependent on timely execution of its ANDA pipeline and Apnar ramp-up; any delays in approvals, scale-up challenges, or slower-than-expected commercialization could impact near-term growth visibility.
* Regulatory Compliance Risk: Operating across regulated and emerging markets, the company remains exposed to risks of audit observations, import alerts or approval delays that could impact product timelines and market access.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
